The gene-editing specialist Editas Medicine Inc. is working on preclinical studies to support the filing of its first investigational new drug (IND) application in mid-2018 for a therapy to treat leber congenital amaurosis 10 (LCA10). Patent disputes between two major CRISPR/Cas9 inventors have been going on while those preparations are under way, but decisions largely have been occurring in Editas's favor.
The US Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB) decided in February that there was "no...






